Notes
Note · Renovaro Biosciences Inc.
Reference: 5% Original Issue Discount Convertible Promissory Notes
- Original principal
- USD 2,105,264
- Outstanding
- —
- Commitment
- —
- Availability
- —
- Maturity
- Sep 5, 2024
Last reported interest terms: 12% Reported 2023-10-10 Later filings may not restate these terms; this does not confirm they still apply.
Covenant terms for this agreement are not yet verified.
Documents and filing history
- Issuance · 8-K · 2023-10-10 — FORM 8-K
-
Issuance
· 2023-10-05
Original principal USD 2,105,264 Exact source document
Parent 8-K filing · 2023-10-10
Between September 5, 2023 and October 5, 2023, Renovaro Biosciences Inc. (the “Company”) entered into Subscription Agreements with five investors (the “Investors”) to purchase 5% Original Issue Discount Convertible Promissory Notes (the “Notes”) for an aggregate principal amount of $2,105,264. The Company received a total of $2,000,000 in gross proceeds from the offering, taking into account the 5% original issue discount. The Notes bear an interest rate of 12% per annum and shall mature on September 5, 2024 (the “Maturity Date”). The Notes are convertible into shares of the Company’s common stock only upon the occurrence of a Qualified Offering (as defined below) or upon the Maturity Date. The Company may prepay the Note at any time.
Issuer evidence: Between September 5, 2023 and October 5, 2023, Renovaro Biosciences Inc. (the “Company”) entered into Subscription Agreements with five investors (the “Investors”) to purchase 5% Original Issue Discount Convertible Promissory Notes (the “Notes”) for an aggregate principal amount of $2,105,264. The Company received a total of $2,000,000 in gross proceeds from the offering, taking into account the 5% original issue discount. The Notes bear an interest rate of 12% per annum and shall mature on September 5, 2024 (the “Maturity Date”). The Notes are convertible into shares of the Company’s common stock only upon the occurrence of a Qualified Offering (as defined below) or upon the Maturity Date. The Company may prepay the Note at any time.
Supporting evidence: Between September 5, 2023 and October 5, 2023, Renovaro Biosciences Inc. (the “Company”) entered into Subscription Agreements with five investors (the “Investors”) to purchase 5% Original Issue Discount Convertible Promissory Notes (the “Notes”) for an aggregate principal amount of $2,105,264. The Company received a total of $2,000,000 in gross proceeds from the offering, taking into account the 5% original issue discount. The Notes bear an interest rate of 12% per annum and shall mature on September 5, 2024 (the “Maturity Date”). The Notes are convertible into shares of the Company’s common stock only upon the occurrence of a Qualified Offering (as defined below) or upon the Maturity Date. The Company may prepay the Note at any time.